ASCO 2025 | How will neoadjuvant endocrine therapy improve outcomes in ILC?

Jason Mouabbi • 31 May 2025

ASCO 2025

Breast Cancer

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the potential of combining endocrine therapy with targeted therapies in invasive lobular carcinoma (ILC). Dr Mouabbi emphasizes the need to establish a backbone for endocrine therapy in a specific subtype of breast cancer, paving the way for future studies combining endocrine therapy with targeted therapies such as CDK4/6 inhibitors and AKT inhibitors. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Endocrine therapies are not given alone anymore, they are given with targeted therapies. But we need to start somewhere to prove that endocrine therapy, at least as a backbone, is feasible for that subtype of breast cancer. So that study will solidify its place and the future will be combining endocrine therapy with targeted therapy like CDK4/6 inhibitor, AKT inhibitor, PI3KCA inhibitor, and so forth...

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.